Issue 17, 2017

Podophyllotoxin–pterostilbene fused conjugates as potential multifunctional antineoplastic agents against human uveal melanoma cells

Abstract

Uveal melanoma is the most common primary intraocular malignancy with a high tendency for early metastasis. There is an urgent need for novel anticancer agents for the therapy of uveal melanoma. In this paper, two novel conjugates of podophyllotoxin–pterostilbene were prepared and evaluated for their cytotoxicity against human uveal melanoma cells (MUM-2B and C918) by the CCK-8 assay. Conjugate B1 exhibited a significant IC50 value of 0.081 ± 0.004 μM against MUM-2B cells. Treatment of MUM-2B cells with B1 caused S cell cycle arrest through reductions in CyclinB1, CDK1 and CDK2 levels. In addition, B1 showed antimigratory activity by down-regulating the expression of VEGFR-2 and MMP-2, and up-regulating the level of E-cadherin. Furthermore, B1 treatment resulted in the induction of apoptosis as characterized by Hoechst 33342 staining, flow cytometry and cleavage of procaspases-3, -8, and -9. Finally, B1 significantly inhibited TOPOIIα and TOPOIIβ expression, simultaneously suppressing the ERK1/2 and AKT pathways in MUM-2B cells.

Graphical abstract: Podophyllotoxin–pterostilbene fused conjugates as potential multifunctional antineoplastic agents against human uveal melanoma cells

Article information

Article type
Paper
Submitted
29 Dec 2016
Accepted
02 Feb 2017
First published
07 Feb 2017
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2017,7, 10601-10608

Podophyllotoxin–pterostilbene fused conjugates as potential multifunctional antineoplastic agents against human uveal melanoma cells

L. Zhang, J. Wang, L. Liu, C. Zheng, Y. Wang, Y. Chen and G. Wei, RSC Adv., 2017, 7, 10601 DOI: 10.1039/C6RA28832D

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements